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ABSTRACT
Estrogen–DNA adducts are potential biomarkers
for assessing the risk and development of
estrogen-associated cancers. 4-Hydroxyequilenin
(4-OHEN) and 4-hydroxyequilin (4-OHEQ), the
metabolites of equine estrogens present in
common hormone replacement therapy (HRT) for-
mulations, are capable of producing bulky
4-OHEN–DNA adducts. Although the formation of
4-OHEN–DNA adducts has been reported, their
quantitative detection in mammalian cells has not
been done. To quantify such DNA adducts, we
generated a novel monoclonal antibody (4OHEN-1)
specific for 4-OHEN–DNA adducts. The primary
epitope recognized is one type of stereoisomers of
4-OHEN–dA adducts and of 4-OHEN–dC adducts in
DNA. An immunoassay with 4OHEN-1 revealed a
linear dose–response between known amounts of
4-OHEN–DNA adducts and the antibody binding to
those adducts, with a detection limit of approxi-
mately five adducts/10
8 bases in 1mg DNA sample.
In human breast cancer cells, the quantitative
immunoassay revealed that 4-OHEN produces
five times more 4-OHEN–DNA adducts than
does 4-OHEQ. Moreover, in a mouse model for
HRT, oral administration of Premarin increased
the levels of 4-OHEN–DNA adducts in various
tissues, including the uterus and ovaries, in a
time-dependent manner. Thus, we succeeded in
establishing a novel immunoassay for quantitative
detection of 4-OHEN–DNA adducts in mammalian
cells.
INTRODUCTION
Hormone replacement therapy (HRT) is widely used to
decrease menopausal symptoms and to protect against
osteoporosis in post-menopausal women (1). However,
long-term HRT increases the incidence of breast (2–4),
ovarian (5,6) and endometrial cancers (7), and the risk
of those cancers increases with increasing duration of
HRT (3–5,8). Premarin (Wyeth–Ayerst) is the most
common drug used for HRT and is composed of approxi-
mately 50% estrogens and 40% equine estrogens
[equilenin (EN) and equilin (EQ)] (9).
In vitro experiments have shown that equine estrogens
are successively metabolized and are capable of forming
various types of DNA damage (9–11) (Figure 1). Like
estrogen, EN and EQ are metabolized by cytochrome
P450 enzymes (CYP) to their 4-hydroxy and 2-hydroxy
forms (9,10). 4-Hydroxyequilenin (4-OHEN) is rapidly
auto-oxidized to an o-quinone (4-OHEN-o-quinone)
which in turn readily reacts with DNA, resulting in the
formation of unique dC, dA and dG adducts (4-OHEN–
DNA adducts) with four possible stereoisomers for each
base adduct (9,11,12) (Figure 2). 4-Hydroxyequilin
(4-OHEQ) is also autoxidized to an o-quinone which
isomerizes to 4-OHEN-o-quinone. As a result, 4-OHEQ
and 4-OHEN produce the same 4-OHEN–DNA adduct
(13). Simultaneously, oxidative DNA damage, such
as 7,8-dihydro-8-oxodeoxyguanine (8-oxodG), is also
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cycling between the o-quinone of 4-OHEN and its semi-
quinone radicals (14).
Indeed, when 4-OHEN was injected into mammary
fat pads of rats, various types of DNA damage, including
4-OHEN-dG, 4-OHEN–dA and 8-oxodG were detected in
the extracted mammary tissues (15). 4-OHEN–DNA
adducts were also detected in two out of the seven DNA
samples from ﬁve human breast tumors and two adjacent
normal tissues of donors with a history of Premarin-based
HRT (16). 4-OHEN-dC and 4-OHEN–dA adducts have
been reported to be frequently miscoded during DNA
synthesis catalyzed by human DNA polymerases that
are highly expressed in reproductive organs (17–22).
Moreover, the treatment of male Syrian hamsters for 9
months with Premarin and a mixture of EN and EQ
resulted in 100% tumor incidence with many tumor foci
in the kidneys (23). These results suggest that 4-OHEN–
DNA adducts are speciﬁc biomarkers for assessing the
risk and development of equine estrogen-associated
cancers.
However, although the formation of 4-OHEN–DNA
adducts has been reported, their quantitative detection
in human or rodent samples has not been accomplished.
Obstacles that hamper such experiments might come from
the technically demanding nature of current methods for
adduct detection (24). One popular current method is
liquid chromatography electrospray ionization tandem
mass spectrometry (LC–MS/MS) (25), which is potentially
one of the most sensitive and accurate methods. However,
it requires complete enzymatic digestion of the sample
DNA into deoxynucleosides for accurate quantiﬁcation
of 4-OHEN base adducts (15,16,26). Moreover, the deter-
mination of each particular type of base adduct may force
the technique close to the detection limit, because sample
DNAs generally contain small amounts of 4-OHEN–
DNA adducts which are theoretically composed of 12 dif-
ferent stereoisomers of dC, dA and dG adducts (9,11,12).
In sharp contrast, most immunoassays using speciﬁc
antibodies are capable of detecting DNA adducts
without DNA hydrolysis (27–31). Therefore, immuno-
assays can be rapid, sensitive and reproducible, and can
Figure 1. Metabolic pathway of equine estrogens.
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adducts within individual cells or a tissue. Moreover, they
do not require radiolabeled compounds or expensive
specialized instruments. However, since immunoassays
using an antibody as a probe are indirect methods, the
selective binding of the antibody to the speciﬁc DNA
lesion is essential. For this reason, a monoclonal
antibody speciﬁc for the DNA lesion appears to be the
best choice, but as yet no monoclonal antibodies speciﬁc
for 4-OHEN–DNA adducts have been established.
In the present study, we generated a novel monoclonal
antibody that is highly speciﬁc for 4-OHEN–DNA
adducts. An immunoassay with that antibody revealed a
linear dose–response between known amounts of
4-OHEN–DNA adducts and the antibody binding to
those adducts. In human breast cancer cells, the quantita-
tive immunoassay revealed that 4-OHEN produces ﬁve
times more 4-OHEN–DNA adducts than does 4-OHEQ.
Moreover, in a mouse model for HRT, oral administra-
tion of Premarin increased the levels of 4-OHEN–DNA
adducts in various tissues, including the uterus and
ovaries, in a time-dependent manner.
MATERIALS AND METHODS
Chemicals
4-OHEN, 4-OHEQ and 4-OHEN-modiﬁed DNA contain-
ing 5.2 4-OHEN–dC adducts/10
4 bases and 1.2 4-OHEN–
dA adducts/10
4 bases were prepared as described previ-
ously (12,19). 4-OHEN and 4-OHEQ were dissolved in
acetone. An oligonucleotide containing a single 4-OHEN
adduct (4-OHEN-oligo; 50 -TTTGTXTTTT-30) (where X
is a stereoisomer of 4-OHEN-dA or 4-OHEN-dC) was
prepared as described previously (17,19). An oligonucleo-
tide containing a single deoxyguanosine-N
2-6b-estradiol
(dG-N
2-6b-E2)( 5 0-GAGGTGCXTGTTTGT-30) (where
X is dG-N
2-6b-E2) was also prepared as described previ-
ously (32). Unmodiﬁed oligonucleotides and methylated
bovine serum albumin (mBSA) were purchased from
Sigma Genosys Japan (Ishikari, Hokkaido, Japan)
and from Calbiochem (San Diego, CA), respectively.
N-Acetoxy-2-acetylaminoﬂuorene-modiﬁed DNA (AAF-
DNA) was prepared as described previously (31).
UV-irradiated DNA (UV-DNA) was prepared by irradi-
ation with 254-nm UV at 300J/m
2. Premarin was
purchased from Wyeth–Ayerst (Philadelphia, PA).
Cell culture
Mouse myeloma cells (P3X63Ag8.653; Flow Laboratories,
McLean, VA) and human breast cancer cells (MCF-7; a
kind gift from Dr K. Shimoi, University of Shizuoka,
Shizuoka, Japan) were cultured in Dulbecco’s modiﬁed
Eagle’s medium (Nissui Seiyaku, Tokyo, Japan) supple-
mented with 10% fetal bovine serum and antibiotics. We
designate this culture medium as growth medium.
Immunization
All animal experiments in this study were conducted
according to the Guidelines for Animal Welfare and
Experimentation at Nara Medical University.
4-OHEN-modiﬁed DNA described above was dissolved
in phosphate-buﬀered saline (PBS; pH 7.4) and denatured
by heating in boiled water for 10min followed by rapid
chilling in an ice bath. 4-OHEN-modiﬁed single-stranded
DNA (4-OHEN-ssDNA; 500mg/ml) was electrostatically
conjugated with 500mg/ml mBSA. The complex was then
emulsiﬁed with an equal volume of complete Freund’s
adjuvant (Difco Laboratories, Detroit, MI) and used
as an immunogen. BALB/c mice (7-week-old female;
Oriental BioService, Kyoto, Japan) were injected
Figure 2. Structures of 4-OHEN–DNA adducts and their stereoisomers. 4-OHEN–dA and 4-OHEN–dC form similar stereoisomers with four dif-
ferent types. dA1/dC1, 4-OHEN–dA1/4-OHEN–dC1; dA2/dC2, 4-OHEN–dA2/4-OHEN–dC2; dA3/dC3, 4-OHEN–dA3/4-OHEN–dC3; dA4/dC4,
4-OHEN–dA4/4-OHEN–dC4.
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0.5ml). Similar immunizations were carried out 2, 4 and 6
weeks later. One week after the fourth immunization, a
booster injection of the immunogen without adjuvant was
given into the tail vein.
Preparation of hybridoma cells
Three days after the booster injection, the spleen of the
mouse was removed and dissociated by passage through
100-mesh steel gauze. The spleen cells (2 10
8) were fused
with an equal number of myeloma cells in the presence of
50% polyethylene glycol 1500 (Boehringer Mannheim).
The fused cells were suspended in selective growth
medium (33) supplemented with 5% BriClone
(Archport, Dublin, Ireland). The cell suspension (2 10
5
hybrid cells) was distributed into each well of 96-well
culture plates and cultured with periodic changes of
medium. Supernatants from wells containing hybridoma
colonies were screened for the presence of speciﬁc
antibodies using a direct enzyme-linked immunosorbent
assay (ELISA) described below. The hybridoma cells
from a positive well were cloned twice by limiting
dilution. The clone was expanded in culture, and
antibody-rich supernatants were concentrated by
ammonium sulfate precipitation, dialyzed against PBS
and stored at  80 C.
ELISA
Binding of the monoclonal antibodies to antigens was
measured using an ELISA (a direct ELISA).
Polyvinylchloride ﬂat-bottom 96-well microtiter plates
(Thermo, Milford, MA; Part No. 2801), precoated with
0.003% protamine sulfate, were coated with
4-OHEN-ssDNA or ssDNA overnight at 37 C. After
washing ﬁve times with PBS-T (0.05% Tween-20 in
PBS), the plates were blocked with 2% fetal bovine
serum in PBS for 30min. After washing ﬁve times with
PBS-T, the solid-phase antigens were detected by 30-min
incubation with the monoclonal antibodies described
below. The plates were washed ﬁve times with PBS-T,
followed by 30-min incubation with goat anti-mouse
IgG conjugated to peroxidase (diluted 1:3000 in PBS;
Zymed, South San Fransisco, CA). After washing ﬁve
times with PBS-T, the plates were ﬁnally incubated with
the substrate solution consisting of 0.04% o-phenylene
diamine and 0.007% H2O2 in citrate-phosphate buﬀer
(pH 5.0) for 30min. After stopping the reaction with
2M H 2SO4, the absorbance of colored products derived
from o-phenylene diamine was measured at 492nm. To
determine very low levels of 4-OHEN–DNA adducts, a
biotin–streptavidin system was adopted to a direct
ELISA (a sensitive direct ELISA). The method was
the same as that described above, except that goat
anti-mouse IgG conjugated to biotin, F(ab0)2 fragment
(diluted 1:2000 in PBS; Zymed) and then to
streptavidin-multiple-peroxidase (diluted 1:2500 in PBS;
AMDEX, GE Healthcare UK, Little Chalfont, UK)
were used instead of goat anti-mouse IgG conjugated to
peroxidase. For the competitive inhibition assay with
ELISA (a competitive ELISA), the plates were coated
with 4-OHEN-ssDNA. The method was the same as
that used with the sensitive direct ELISA, except that in
addition to utilizing streptavidin-peroxidase (diluted
1:10000 in PBS; Zymed) instead of streptavidin-
multiple-peroxidase, the amount of monoclonal anti-
body which gives 50% of the maximum binding to
the solid-phase antigen and various concentrations
of the competitor were successively added as described
previously (31).
Generation of a standard dose–response curve
DNA samples containing various known amounts of
DNA adducts (5–50 adducts/10
8 bases) were prepared
by mixing 4-OHEN-modiﬁed DNA described above and
unmodiﬁed DNA in diﬀerent ratios. After coating their
heat-denatured samples on plates (1mg/well), the sensitive
direct ELISA with the antibody (diluted 1:1000 in PBS)
was performed to generate a standard dose–response
curve between the amounts of 4-OHEN–DNA adducts
and the antibody binding to those adducts. A standard
dose–response curve was generated in each ELISA experi-
ment for determining the absolute amount of 4-OHEN–
DNA adducts in sample DNA. For analysis of statistical
signiﬁcance, Student’s t-tests were performed between
modiﬁed and unmodiﬁed DNA samples.
Measurement of induction of 4-OHEN–DNA adducts in
human breast cancer cells
MCF-7 cells were cultured in 100-mm dishes and were
exposed to various concentrations of 4-OHEN or
4-OHEQ for 3h. After washing twice with Dulbecco’s
PBS (DPBS), cells were harvested using a cell scraper
and genomic DNAs of the cells were puriﬁed using a
QIAamp Blood Kit (QIAGEN, Hilden, Germany). Each
heat-denatured DNA sample (1mg) was coated in quadru-
plicate in each well of a 96-well microtiter plate. 4-OHEN–
DNA adducts were then detected using the sensitive direct
ELISA and quantiﬁed using the standard dose–response
curve obtained from the same plate.
Measurement of induction of 4-OHEN–DNA adducts in
various mouse tissues
As a mouse model for HRT, female BALB/c mice (9
months old; Oriental BioService) were fed powdered
food (CE-2, Clea Japan, Tokyo, Japan) mixed with or
without powdered Premarin tablets (20.7mg/g) for 4 or
12 weeks. Each group consisted of ﬁve mice. The intake
of food and the body weights of mice were measured twice
a week during the experiment. The average daily intake of
Premarin for each mouse was 74mg/32g body weight,
which is roughly 100 times higher than the human daily
dose (1.25mg/60kg body weight) used for HRT. After
completing the drug treatment, the mice were sacriﬁced
and ﬁve diﬀerent tissues (liver, kidney, spleen, uterus
and ovary) of each mouse were removed, quickly frozen
in liquid nitrogen and stored at  80 C. After being
thawed and minced, DNA was extracted from each
tissue using the standard phenol–chloroform method.
4-OHEN–DNA adducts were then detected using the sen-
sitive direct ELISA and quantiﬁed using the standard
e133 Nucleic Acids Research, 2010,Vol.38, No. 12 PAGE 4 OF 9dose–response curve obtained from the same plate. For
analysis of statistical signiﬁcance, Student’s t-tests were
performed between treated and untreated samples.
RESULTS
Generation of a novel monoclonal antibody, 4OHEN-1
Supernatants from 404 wells containing hybridoma cells
were tested for production of antibodies that could bind
4-OHEN-ssDNA and/or ssDNA using the direct ELISA,
and one was found to have preferential binding to
4-OHEN-ssDNA. After cloning those cells twice, we
designated the monoclonal antibody as 4OHEN-1.
Isotype analysis (Serotec, Oxford, UK) revealed that
4OHEN-1 is of the IgG1 (kappa) subclass.
The antibody is highly speciﬁc for 4-OHEN–DNA
adducts such as 4-OHEN-dC and 4-OHEN-dA
To characterize the binding speciﬁcity of 4OHEN-1, dif-
ferent dilutions of it were tested for binding to
4-OHEN-ssDNA and to ssDNA using the direct ELISA
(Figure 3A). 4OHEN-1 showed high binding to
4-OHEN-ssDNA but had undetectable or minimal
binding to undamaged ssDNA. We next examined
whether 4OHEN-1 speciﬁcally binds to 4-OHEN–DNA
adducts but not to other types of DNA damage using
the competitive ELISA (Figure 3B). 4-OHEN-ssDNA ef-
ﬁciently inhibited antibody binding to 4-OHEN-ssDNA,
but UV-ssDNA, AAF-ssDNA or undamaged ssDNA did
not, indicating that 4OHEN-1 speciﬁcally binds to
4-OHEN–DNA adducts but does not bind to general
DNA helix distortions induced by various types of DNA
damage. It has been suggested that 4-OHEN–DNA
adducts include 4-OHEN–dC, 4-OHEN–dA and
4-OHEN–dG, with four diﬀerent stereoisomers for each
base adduct (4-OHEN–dC1–4, 4-OHEN–dA1–4 and
4-OHEN–dG1–4) (34–39) (Figure 2). Among those
adducts, the 4-OHEN–dC3,–dC4,–dA3 and–dA4
isomers are thought to be the major types (12,24,40).
We examined whether those isomers comprised the anti-
genic determinant in the 4-OHEN–DNA adducts
recognized by 4OHEN-1 (Figure 4). Indeed, oligonucleo-
tides containing 4-OHEN–dC3,–dC4,–dA3 or–dA4 in-
hibited the antibody binding to 4-OHEN-ssDNA in a
concentration-dependent manner. The 4-OHEN–dC3
and–dA3 isomers showed higher inhibition of antibody
binding than did the 4-OHEN–dC4 and–dA4 isomers,
indicating that the 4-OHEN–dC3 and–dA3 isomers
of DNA are the primary epitope recognized by
4OHEN-1. We conﬁrmed that 4OHEN-1 does not bind
to a DNA adduct derived from endogenous estrogen
Figure 3. The novel monoclonal antibody is speciﬁc for 4-OHEN-DNA adducts. (A) The antibody shows high binding to 4-OHEN-ssDNA but
undetectable or minimal binding to undamaged ssDNA. Diﬀerent dilutions of the antibody were tested for binding to immobilized denatured
antigens (50ng/well) using a direct ELISA. (B) The antibody binds to 4-OHEN–DNA adducts but not to other types of DNA damage.
Competitive inhibition of the antibody (1/10000) binding to immobilized 4-OHEN-ssDNA (40ng/well) by various competitors was performed
using a competitive ELISA. (C) The antibody does not bind to a DNA adduct derived from endogenous estrogen (17b-estradiol). Competitive
inhibition of the antibody (1/3000) binding to immobilized 4-OHEN-ssDNA (5ng/well) by various competitors was performed using a competitive
ELISA. oligo, oligonucleotide; dG-N
2-6b-E2-oligo, oligonucleotide containing a deoxyguanosine-N
2-6b-estradiol. Each point shows the mean (±SD)
of three independent experiments.
Figure 4. The primary epitope recognized is contained in 4-OHEN–
dA3 and –dC3 adducts in DNA. Competitive inhibition of antibody
(1/3000) binding to immobilized 4-OHEN-ssDNA (5ng/well) by
various competitors was performed using a competitive ELISA. oligo,
oligonucleotide; dA3, 4-OHEN–dA3-oligo; dA4, 4-OHEN–dA4-oligo;
dC3, 4-OHEN–dC3-oligo; dC4, 4-OHEN-dC4-oligo. Each point
shows the mean (±SD) of three independent experiments.
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2-6b-estradiol (dG-N
2-
6b-E2) (Figure 3C). Taken together, these results demon-
strate that 4OHEN-1 is highly speciﬁc for 4-OHEN–DNA
adducts in DNA such as 4-OHEN–dC and –dA isomers.
A linear standard dose–response curve was obtained
4OHEN-1 was used in the sensitive direct ELISA to detect
4-OHEN-derived adducts in DNA. A linear standard
dose–response curve between amounts of 4-OHEN–
DNA adducts coated in the wells (5–50 adducts/10
8
bases) and antibody binding was obtained (Figure 5). A
similar linear dose–response was also obtained at a higher
dose range (25–300 adducts/10
8 bases) (data not shown).
Student’s t-tests indicated signiﬁcant diﬀerences (P<0.05)
in OD values between DNA containing zero adduct and
ﬁve adducts per 10
8 bases.
4-OHEN and 4-OHEQ produce 4-OHEN–DNA adducts
in a dose-dependent manner in human breast cancer cells
Premarin includes two types of equine estrogens (EN and
EQ), thus we examined whether either of their metabolites
(4-OHEN and 4-OHEQ) induce 4-OHEN–DNA adducts
in MCF-7 cells using the sensitive direct ELISA (Figure 6).
We found that 3-h exposure to either chemical produces
4-OHEN–DNA adducts in a concentration-dependent
manner, and that 4-OHEN forms ﬁve times more
4-OHEN–DNA adducts than does 4-OHEQ.
Oral administration of Premarin induces 4-OHEN–DNA
adducts in tissues of aged female mice
To verify that oral administration of Premarin results in
the formation of 4-OHEN–DNA adducts in tissues of
aged female mice, quantitative detection of the DNA
adducts was performed using the sensitive direct ELISA
(Figure 7). In mice treated with Premarin for 4 weeks,
4-OHEN–DNA adducts were detected in the liver,
spleen and ovary (with 4.5, 3.9 and 2.5 adducts per 10
8
bases, respectively) but were not detected in the kidney or
uterus, though these amounts are close to the detection
limit. The levels of DNA adducts increased in all tissues
examined in mice treated with Premarin for 12 weeks. We
detected 10.9, 0.48, 10.3, 13.1 and 7.6 adducts per 10
8
bases, respectively, in the liver, kidney, spleen, uterus
and ovary. Those amounts of DNA adducts were statis-
tically signiﬁcant except in the kidney. These results
indicate that oral administration of Premarin induces
4-OHEN–DNA adducts in a time-dependent manner,
and that relatively similar amounts of DNA adducts are
produced in the tissues examined except for the kidney.
DISCUSSION
A novel monoclonal antibody (4OHEN-1) has been
generated that is speciﬁc for 4-OHEN-DNA adducts,
and the primary epitope recognized is contained in the
4-OHEN–dC3 and –dA3 adducts (Figure 2). The
presence of the 4–OHEN-derived structure common to
4-OHEN–dC and–dA adducts accounts for this. We
have not determined the binding activity to 4-OHEN–
dG adducts because of the unavailability of oligonucleo-
tides containing them. As the 4-OHEN–dC and–dA
adducts are known to be the major products generated
in DNA treated with 4-OHEN (12,24,40), this binding
speciﬁcity is advantageous to increase the sensitivity for
the detection of 4-OHEN–DNA adducts. We have previ-
ously prepared a monoclonal antibody speciﬁc for
AAF-DNA adduct (31). Although two types of AAF
Figure 5. The sensitive direct ELISA reveals the linear dose–response
between the amounts of 4-OHEN-DNA adducts and the antibody
binding to those adducts. After coating denatured DNA samples con-
taining various known amounts of DNA adducts on plates (1mg/well),
the sensitive direct ELISA with the antibody (1/1000) was performed to
generate a standard dose–response curve. Each point shows the mean
(± SD) of four independent experiments.
Figure 6. 4-OHEN produces ﬁve times more 4-OHEN–DNA adducts
than does 4-OHEQ. MCF-7 cells were exposed to either 4-OHEN or
4-OHEQ in various concentrations for 3h. The induction of 4-OHEN–
DNA adducts was then quantiﬁed using the sensitive direct ELISA as
shown in Figure 5. Each point shows the mean (±SD) of three inde-
pendent experiments.




2-AAF)] are produced at guanine
sites of DNA, the antibody can discriminate between the
adducts, binds speciﬁcally to the former but not to the
latter. Moreover, when dG-C8-AAF is slightly changed
into dG-C8-AF by deacetylation, the binding aﬃnity is
reduced by more than 10-fold, showing its highly speciﬁc
binding. Similarly, in the present study, the binding
aﬃnity to another stereoisomer of 4-OHEN–dC and–dA
adducts is reduced by 10-fold or more (Figure 4),
indicating the excellent binding speciﬁcity of 4OHEN-1.
Indeed, the antibody did not cross-react with a DNA
adduct derived from endogenous estrogen;
deoxyguanosine-N
2-6b-estradiol that lacks an OH
moiety from the DNA adduct derived from 2-OHE2
(Figure 3C). Regarding the cross-reactivity with
4-OHEN–RNA adducts, it is unable to test because no
identiﬁed standards are available. However, this issue
seems not to much aﬀect the practical detection using a
sensitive direct ELISA, since RNA is carefully removed
during extracting DNA. The 4OHEN-1 antibody binds to
4-OHEN–DNA adducts with high aﬃnity, and the 50%
antibody-binding inhibition values for 4-OHEN–dC3
and–dA3 adducts were calculated as 8.83 10
 10M and
1.57 10
 9M, respectively (Figure 4). Those values are
superior or comparable to those of other useful polyclonal
and monoclonal antibodies that recognize carcinogen–
DNA adducts (31,41). Moreover, the 4OHEN-1
antibody is capable of binding to 4-OHEN adducts
without requiring the hydrolysis of the DNA to nucleo-
sides. This is a very important property of an antibody for
damage detection, because this enables it to be applied in
immunoﬂuorescence to visualize DNA adducts in cells or
tissues, to save time for experiments and to avoid a
possible decrease in detection sensitivity due to incomplete
DNA hydrolysis (24). Indeed, 4-OHEN–DNA adducts
were visualized in the nuclei of 4-OHEN-treated MCF-7
cells by using immunoﬂuorescence with 4OHEN-1 (data
not shown). It is worth noting that all other competitive
methods require DNA hydrolysis for damage detection
(12,15,16,26).
Based on these promising results, 4OHEN-1 was
applied in ELISA to determine 4-OHEN-derived
adducts in various DNA samples. It is worth noting that
only monoclonal antibodies with high speciﬁcity (not
polyclonal antibodies) are practically applicable to a
direct binding ELISA. The sensitive direct ELISA
revealed a linear dose–response between known amounts
of 4-OHEN–DNA adducts (5–50 adducts/10
8 bases) and
the antibody binding to those adducts (Figure 5). There
are signiﬁcant diﬀerences (P<0.05) in OD values between
DNA containing zero adduct and ﬁve adducts per 10
8
bases, indicating that the sensitive ELISA can detect ﬁve
adducts/10
8 bases in 1mg DNA sample at least. A similar
linear dose–response was also obtained at a higher dose
range (25–300 adducts/10
8 bases). These results suggest
the validity of the present DNA sample preparation for
calibration, which was done by mixing 4-OHEN-modiﬁed
DNA and unmodiﬁed DNA in diﬀerent ratios. This is
supported by our previous report demonstrating that the
detection of UV-induced DNA lesions by the direct
binding ELISA is not much inﬂuenced by their distribu-
tion (dense or sparse) within DNA when equal amounts of
photolesions are induced (42). The standard curve
generated in each ELISA experiment is essential for
determining the absolute amount of 4-OHEN–DNA
adducts in sample DNA. Two types of equine estrogens
(EN and EQ) are contained in Premarin, and their metab-
olites (4-OHEN and 4OHEQ, respectively) were found to
induce 4-OHEN–DNA adducts in MCF-7 cells (Figure 6).
About 90 DNA adducts per 10
8 bases were induced after
3-h exposure to 200mM 4-OHEN. Interestingly, 4-OHEN
produced ﬁve times more 4-OHEN–DNA adducts than
did 4-OHEQ. This suggests that although EN represents
about one-third of the content of EQ in Premarin, EN is
still responsible for more induction of 4-OHEN–DNA
adducts than is EQ. In a mouse model for HRT, oral
administration of Premarin increased the levels of
4-OHEN-DNA adducts in various tissues, including
the uterus and ovaries, in a time-dependent manner
(Figure 7). This suggests that 4-OHEN–DNA adducts
may be induced in women receiving HRT for long
periods (16), and that those adducts could be determined
by increasing the sensitivity of the ELISA.
Many evidence suggests that 4-OHEN–DNA adducts
are speciﬁc biomarkers for assessing the risk and develop-
ment of equine estrogen-associated cancers. The present
new approach utilizing monoclonal antibodies that are
highly speciﬁc for such DNA adducts provides a
valuable and sensitive detection method. This method
Figure 7. Oral administration of Premarin induces 4-OHEN–DNA
adducts in tissues of aged female mice. As a mouse model for HRT,
9-month-old female mice were orally treated with Premarin for 4 or 12
weeks. 4-OHEN–DNA adducts in tissues of each mouse were then
quantiﬁed using the sensitive direct ELISA as shown in Figure 5.
Each bar shows the mean (±SD) of ﬁve independent experiments.
Signiﬁcant diﬀerences between Premarin-treated and untreated
samples are noted (*P<0.05, **P<0.01). N.D.; not detected.
PAGE 7 OF 9 Nucleic Acids Research, 2010,Vol.38, No. 12 e133could prove very useful in identifying individuals harbor-
ing 4-OHEN–DNA adducts; they could then be counseled
to avoid hormone replacement drugs such as Premarin
whose formulations include equine estrogens that are
capable of producing these kinds of DNA lesions.
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